Cefpodoxime proxetil
Brand name: Vantin® (and others)
A prodrug of the active antibacterial agent cefpodoxime, a third‑generation cephalosporin.
---
1. FDA‑Approved Indications
| Infection Site | Typical FDA‑approved indication (adult) |
|----------------|------------------------------------------|
| Lower respiratory tract (e.g., acute bronchitis, community‑acquired pneumonia) | 400 mg PO twice daily (or 200 mg PO once daily) for 7–10 days |
| Upper respiratory tract (e.g., pharyngitis, sinusitis) | 400 mg PO twice daily (or 200 mg PO once daily) for 7–10 days |
| Urinary tract infections (acute cystitis, uncomplicated pyelonephritis) | 400 mg PO twice daily (or 200 mg PO once daily) for 7–10 days |
| Skin & skin‑structure infections (abscess, cellulitis, erysipelas) | 400 mg PO twice daily (or 200 mg PO once daily) for 7–10 days |
| Dental infections (periapical abscesses, dental abscesses) | 400 mg PO twice daily (or 200 mg PO once daily) for 7–10 days |
Note: The FDA label lists the drug as “a broad‑spectrum, third‑generation cephalosporin antibiotic for the treatment of bacterial infections of the upper and lower respiratory tract, urinary tract, skin and skin‑structure infections, and dental infections.”
---
2. How It Works
| Step | What Happens |
|------|--------------|
| 1. Oral administration | Cefpodoxime proxetil is a lipophilic prodrug that is absorbed through the gastrointestinal tract. |
| 2. Prodrug conversion | Intestinal enzymes (esterases) convert cefpodoxime proxetil to the active drug cefpodoxime. |
| 3. Mechanism of action | Cefpodoxime binds bacterial penicillin‑binding proteins (PBPs), inhibiting cell‑wall peptidoglycan synthesis → bactericidal effect. |
| 4. Spectrum | Effective against many Gram‑positive (e.g., Streptococcus pneumoniae, Staphylococcus aureus) and Gram‑negative organisms (e.g., Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae). Resistant strains include many β‑lactamase producers; however, cefpodoxime shows activity against many β‑lactamase–producing strains that are susceptible to third‑generation cephalosporins. |
---
3. Typical Dosing Guidelines
| Population | Dose | Frequency | Duration |
|------------|------|-----------|----------|
| Adults & Adolescents (≥ 12 y) | 400 mg PO twice daily (or 200 mg PO once daily if tolerated) | 7–10 days | For most infections |
| Children (5–12 y) | 10 mg/kg PO twice daily (max 400 mg) | 7–10 days | For respiratory, UTI, skin, dental infections |
| Infants (1–5 y) | 10 mg/kg PO twice daily (max 400 mg) | 7–10 days | As above |
Dose adjustments: No routine renal dose adjustment for mild‑to‑moderate CKD; dose may be reduced or frequency changed for severe renal impairment or dialysis.
---
4. Contraindications
| Category | Specifics |
|----------|-----------|
| Allergy | Known hypersensitivity to cefpodoxime, other cephalosporins, or any component of the formulation (e.g., 4‑hydroxy‑2‑methyl‑pyrimidine). |
| Severe allergic reaction | Anaphylaxis, angioedema, or severe urticarial rash after previous cephalosporin exposure. |
| Pregnancy | Category B. Avoid in first trimester unless clearly needed; consult obstetrician. |
| Lactation | Excreted in milk; usually avoided unless benefits outweigh risks. |
---
5. Warnings & Precautions
| Issue | Key Points |
|-------|------------|
| Antimicrobial Resistance | Overuse promotes resistance. Reserve for infections where cefpodoxime is appropriate. |
| Clostridioides difficile | Rare but possible. Monitor for diarrhea; discontinue if signs of pseudomembranous colitis. |
| Renal Impairment | No dose adjustment for mild‑to‑moderate CKD. In severe CKD or dialysis, monitor drug levels and adjust dose accordingly. |
| Pregnancy & Lactation | Category B; avoid in first trimester if possible. |
| Gastrointestinal | May cause nausea, vomiting, diarrhea; take with food if GI upset occurs. |
| Drug‑Drug Interactions | Minimal significant interactions, but caution with drugs that alter GI pH or motility. |
---
6. Adverse Reactions (Common, < 10 %)
| Class | Examples |
|-------|----------|
| GI | Nausea, vomiting, diarrhea, abdominal pain |
| Allergic | Rash, pruritus, mild angioedema (rare) |
| Hematologic | Rare thrombocytopenia, leukopenia |
| Hepatic | Transient elevation of ALT/AST (usually < 3× ULN) |
Serious reactions: Severe cutaneous adverse reactions (SJS/TEN), anaphylaxis, Clostridioides difficile colitis. Report any severe or persistent adverse event to a clinician.
---
7. Drug Interactions
| Drug | Interaction | Clinical Relevance |
|------|-------------|--------------------|
| Probenecid | Increases plasma cefpodoxime levels by reducing renal excretion. | May require dose adjustment or monitoring. |
| Metformin | Minor interaction; no dose adjustment needed. |
| Antacids or high‑pH agents | Potentially reduce absorption. | Take 2 hrs before/after. |
| Other β‑lactams | No major interactions, but concurrent use may increase risk of hypersensitivity. |
---
8. Pharmacokinetics (Adult)
| Parameter | Typical Value |
|-----------|---------------|
| Absorption | 80–90 % oral; peak plasma concentration in 0.5–3 hr. |
| Bioavailability | ~80 % after conversion from prodrug. |
| Half‑life | ~2.5 hr (depends on renal function). |
| Protein binding | 20–35 %. |
| Renal clearance | Primary route of excretion; ~80 % unchanged drug in urine. |
| Food effect | Slightly reduced peak concentration; overall bioavailability not clinically significant. |
---
9. Practical Tips for Clinicians
1. Choose the right agent: Use cefpodoxime when local antibiograms show susceptibility to third‑generation cephalosporins and when oral therapy is preferable.
2. Duration: Keep the duration to the minimum effective period (usually 7–10 days). Shorter courses are often equally effective and reduce resistance risk.
3. Monitor renal function: Especially in the elderly or those with CKD; consider dose adjustment for severe impairment.
4. Patient counseling:
- Take with food if GI upset occurs.
- Complete the full course even if symptoms improve.
- Report any rash, swelling, or severe GI symptoms promptly.
5. Special populations:
- Pregnancy: Use only if benefits outweigh potential risks; avoid first trimester if possible.
- Pediatrics: Weight‑based dosing; monitor growth and development.
---
10. Quick Reference – FDA‑Labeled Uses (Allergen‑free)
- Upper Respiratory Tract Infections – Pharyngitis, sinusitis
- Lower Respiratory Tract Infections – Acute bronchitis, community‑acquired pneumonia
- Urinary Tract Infections – Acute cystitis, uncomplicated pyelonephritis
- Skin & Skin‑Structure Infections – Abscesses, cellulitis, erysipelas
- Dental Infections – Periapical abscess, dental abscess
All doses are for adults; pediatric doses are weight‑based.
---
Bottom Line
Cefpodoxime proxetil is a convenient oral third‑generation cephalosporin with a broad spectrum suitable for a variety of common bacterial infections—respir